Details for Patent: 7,671,032

Summary for Patent: 7,671,032

Title:	HCV NS-3 serine protease inhibitors
Abstract:	Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
Inventor(s):	Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
Assignee:	Medivir AB
Application Number:	US10/572,349
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,671,032

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,671,032

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	0400199	Jan 30, 2004
Sweden	0401288	May 19, 2004
Sweden	0402562	Oct 22, 2004

PCT Information
PCT Filed	January 28, 2005	PCT Application Number:	PCT/SE2005/000097
PCT Publication Date:	August 11, 2005	PCT Publication Number:	WO2005/073195

International Family Members for US Patent 7,671,032

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1713823		C300703	Netherlands
European Patent Office	1713823		CA 2014 00059	Denmark
European Patent Office	1713823		1490064-1	Sweden
European Patent Office	1713823		92595	Luxembourg